Navigation Links
Clot-Busting Treatment Improves Bleeding Stroke Outcomes
Date:5/14/2008

Low dose tPA dissolved masses 2 to 3 times faster, dramatically boosting survival

WEDNESDAY, May 14 (HealthDay News) -- Researchers report they have dramatically increased the survival rate for people with strokes caused by bleeding within the brain by fine-tuning the dosage and timing for administering the clot-busting drug tissue plasminogen activator (tPA).

"We've gone from what's usually an 80 percent death rate in patients with this condition to an 80 percent survival rate," study leader Dr. Daniel Hanley, a professor of neurology at the Johns Hopkins University School of Medicine, said in a prepared statement.

This new treatment protocol for intracerebral hemorrhage (ICH) was developed through a multi-center study and reported this week at the European Stroke Conference, in Nice, France.

ICH causes blood to clot inside the brain's interior cavities, building up pressure within the brain. The higher pressure, along with inflammation caused by chemicals in the trapped blood, can irreversibly damage the brain, usually leading to death or extreme disability. No treatment existed for this until recently, Hanley said.

High doses (80 milligrams to 100 milligrams) of tPA have proven effective at breaking up clots in conditions such as heart attacks and other types of strokes, but there was concern that such levels of the drug may cause excessive bleeding in ICH patients. Previous studies showed that giving tPA to ICH patients hadn't significantly increased bleeding or death, so Hanley and his colleagues tested low doses to try to find the safest and most effective treatment regimen possible.

The researchers recruited 52 patients from across the United States, Canada, Great Britain and Germany who were recently diagnosed with ICH. Using the same catheter the patients had received inside the brain to release the trapped blood (the usual treatment for ICH), the researchers flooded tPA directly onto the clot in varying amounts.

The clots dissolved within three to four days on average -- two to three times faster than those of previous patients who didn't receive tPA. The clots of patients receiving 1 milligram of tPA every eight hours dissolved about a day faster than those on lower dose tPA regimens. Additional bleeding was minimal, regardless of what level dose the patients received.

More than 80 percent of the patients were alive one month after treatment. Ten percent of these patients had also recovered enough to return to their jobs, the researchers reported.

"We think that this treatment is the most promising story in brain hemorrhage in many years," Hanley said. "We've taken a condition that used to have an extremely high rate of death and disability and turned it around."

A definitive trial to test this treatment in 500 patients is now being planned by the researchers.

More information

The U.S. Centers for Disease Control and Prevention has more about how to prevent strokes.



-- Kevin McKeever



SOURCE: John Hopkins University, news release, May 14, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Researchers fine-tune clot-busting treatment for bleeding in brain
2. Clot-Busting Drug Offers New Approach to DVT
3. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
4. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
5. Blood-Thinner No Help for Dialysis Treatment
6. Simvastatin Leads Pfizers Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
7. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
8. Medical Research Should Include More Women Participants and Examine the Role of Gender in Disease Incidence and Treatment
9. Homeless youth need more than treatment for substance abuse, study says
10. Newer Prostate Cancer Treatment Similar to Traditional Surgery
11. Improving anxiety treatment through the help of brain imaging: A potential future treatment strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: